The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Actelion Ltd.

Actelion Ltd.
 PROFILE
Actelion walks a fine line. The company and its subsidiaries discover and develop drugs based on their research of the endothelium, the single layer of cells between blood vessels and the blood that flows through them. The endothelium has been linked to such disorders as cancer and cardiovascular and inflammatory diseases. The firm's lead drug candidate, Valetri, failed to improve blood flow in acute heart failure patients, but Actelion is not abandoning the drug yet. The company is also developing Tracleer for congestive heart failure, along with potential treatments for other cardiovascular conditions, cancer, malaria, and Alzheimer's disease. Partners include Genentech and Johnson & Johnson.

 COMPETITION
Merck & Co., Inc. (MRK)
Novartis AG (NVS)
Roche Group (ROHHY)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 19.60
1-Yr. Sales Growth: 983.2%
Employees: 227
Revenue per employee: $86,343.61

 KEY PEOPLE
• Jean-Paul Clozel
    CEO
• André J. Mueller
    CFO

 CONTACT INFO
Gewerbestrasse 16
CH 4123 Allschwil, Switzerland
Phone: 41-61-487-45-16
Fax: 41-61-487-45-00
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001